raised its full-year guidance on Thursday after a
rise in sales of diabetes drug Victoza and synthetic insulins
boosted second-quarter sales and operating profit, beating
forecasts.
Thursday, August 9, 2012
UPDATE 1-Novo Nordisk ups outlook as sales of diabetes drug jump
COPENHAGEN, Aug 9 (Reuters) - Danish drugmaker Novo Nordisk
raised its full-year guidance on Thursday after a
rise in sales of diabetes drug Victoza and synthetic insulins
boosted second-quarter sales and operating profit, beating
forecasts. 
raised its full-year guidance on Thursday after a
rise in sales of diabetes drug Victoza and synthetic insulins
boosted second-quarter sales and operating profit, beating
forecasts.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment